{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002102","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.387361+00:00","generated_at":"2026-06-20T17:24:50.657875+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Novavax appoints John C. Jacobs as CEO; Stanley Erck retires effective Jan 23, 2023","bullets":["John C. Jacobs appointed President and CEO, effective January 23, 2023, succeeding retiring CEO Stanley C. Erck.","Jacobs receives $700k base salary, 75% target bonus, and inducement grants (options + RSUs) worth ~$6M combined.","Erck to provide advisory services through April 2024 at $50k/month for 6 months, then $25k/month, with equity treatment.","Board adopted 2023 Inducement Plan reserving 1 million shares for new-hire equity grants under Nasdaq Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002102","json":"https://secwatch.observer/filing/0001104659-23-002102.json","markdown":"https://secwatch.observer/filing/0001104659-23-002102.md","text":"https://secwatch.observer/filing/0001104659-23-002102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/tm232657d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:24:50.657875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc89b882e8","claim":"Stanley C. Erck retired as President and Chief Executive Officer at NOVAVAX INC.","evidence_excerpt":"Mr. Jacobs will succeed Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f001864444","claim":"John C. Jacobs was appointed as President and Chief Executive Officer at NOVAVAX INC.","evidence_excerpt":"the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) approved the appointment of John C. Jacobs, age 56, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}